Innovus Pharma Acquires Worldwide Rights to Four Products from Boston Topicals

Innovus Pharmaceuticals announced today that the Company has acquired four branded topical products from Boston Topicals, expanding its retail and e-commerce presence in the Company’s current highest revenue grossing category.

The products include the diabetic retail category flagship HealthiFeet, a foot cream, with a published double-blind controlled trial shown to increase temperature and blood flow in feet of diabetic patients and formulated with the KNOSIS transdermal delivery system. Innovus Pharma currently plans to launch the products in its sales and marketing platforms in either the fourth quarter 2018 or the first quarter 2019.

“We continue to bolster our product pipeline with clinically and commercially validated products that fit both our direct to consumer channels as well as retail stores,” said Dr. Damaj, President and CEO of Innovus Pharma.

“HealthiFeet is an excellent candidate for our Beyond Human sales and marketing platform,” said Chris Stella, Vice President of Operations at Innovus Pharma. “We’ve seen tremendous success in this product category with Diabasens, a leg and foot relief topical product, which may exceed approximately $4.5 million in annual revenue this year. We are currently projecting HealthiFeet to become another leader in this space. It also fits well in retail stores where the product has proven to be a category leader with pilot runs at Walmart, CVS and Walgreens and with wholesalers such as McKesson and Cardinal, in which it has had over $1.6 million in cumulative sales,” he continued.